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A B S T R A C T
Purpose
The aims of the TP53 Colorectal Cancer (CRC) International Collaborative Study were to
evaluate the possible associations between specific TP53 mutations and tumor site, and to
evaluate the prognostic and predictive significance of these mutations in different site, stage,
and treatment subgroups.
Patients and Methods
A total of 3,583 CRC patients from 25 different research groups in 17 countries were
recruited to the study. Patients were divided into three groups according to site of the
primary tumor. TP53 mutational analyses spanned exons 4 to 8.
Results
TP53 mutations were found in 34% of the proximal colon tumors and in 45% of the distal
colon and rectal tumors. They were associated with lymphatic invasion in proximal tumors.
In distal colon tumors, deletions causing loss of amino acids were associated with worse
survival. In proximal colon tumors, mutations in exon 5 showed a trend toward statistical
significance (P  .05) when overall survival was considered. Dukes’ C tumors with wild-type
TP53 and those with mutated TP53 (proximal tumors) showed significantly better prognosis
when treated with adjuvant chemotherapy.
Conclusion
Analysis of TP53 mutations from a large cohort of CRC patients has identified tumor site,
type of mutation, and adjuvant treatment as important factors in determining the prognostic
significance of this genetic alteration.
J Clin Oncol 23. © 2005 by American Society of Clinical Oncology
INTRODUCTION
In Western countries, cancers of the colon and
rectum are second only to lung cancer both in
terms of incidence andmortality.1 Although the
mortalityratehasdeclinedinrecentyears,partic-
ularly for rectal cancer, the incidence continues
to increase. Mutation of the TP53 tumor sup-
pressorgene is thought toplayan important role
in the progression of colorectal cancer (CRC)
andmight therefore represent a clinically use-
ful marker of prognosis. The frequency of
TP53mutations inCRC is approximately 40%
to 50%.2 The majority (approximately 80%)
are missense mutations comprising GC to AT
transitions at cytosine phosphate guanine
dinucleotides and occur principally in five
hotspot codons (175, 245, 248, 273, and 282).3
MostTP53mutations occur in exons 5 to 8, in
highly conserved areas, and in three principal
structural domains of the TP53 protein (L2,
L3, and loop-sheet-helix [LSH]).4,5
Several groups have reported that differ-
ent types of TP53 mutation are differentially
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associated with CRC prognosis. These include mutations in
exon 7,6 codon 245,7 conserved areas,8 and the L3 structural
domain.5,9 Results between groups have not always been con-
sistent, however, and this is likely to reflect the insufficient
statistical power of individual studies. Several important issues
should be considered when evaluating the prognostic signifi-
canceofTP53mutations inCRC.First, loss ofTP53 function is
a late event in adenoma-carcinoma progression.10,11 Second,
TP53 mutations have a different incidence and perhaps also
prognostic impact depending on the site of origin of the
tumor in the large bowel. The frequency of TP53mutations
is higher in distal colon and rectal tumors than in proximal
colon tumors.12,13 Third, different frequencies of individual
TP53mutations between populations may also account for
previous discordant results on the prognostic significance
of this genetic alteration.
Furthermore, several clinical studies have reported that
CRC patients with wild-type TP53 derive a survival benefit
from fluorouracil (FU) -based chemotherapy but those
withmutantTP53 do not.2 Hence, the prognostic impact of
TP53 mutation should be evaluated separately for patients
treated with or without adjuvant chemotherapy to avoid
this interaction. The aim of the TP53-CRC International
Collaborative Study was to pool data from a large number
of individual studies to evaluate the prognostic and predic-
tive significance ofTP53mutations inCRCaccording to site
of origin in the large bowel, tumor stage, type of mutation,
and use of adjuvant treatment.
PATIENTS AND METHODS
Recruitment
Beginning in September 2001, different research groups
around the world were invited to participate in this Interna-
tional Collaborative Study. The selection of groups for contact
was by means of a Medline search for publications on TP53
mutations and CRC. A Web page created within the site http://
www.p53.free.fr and entitled “TP53MutationAnalysis inColorec-
tal Cancer: Call for an International Collaborative Study” was also
used to alert research groups to the study. Appropriate groups
identified by the Medline search received a formal invitation to
participate in the study. If an affirmative answer was received, a
questionnaire was sent for the collection of information required
for the study. In all, 25 groups agreed to participate in the study
and returned the completed questionnaires. Individual groups
have published much of the data in this study previously.9,13-33
The names of the communicating authors from each group, their
country of origin, and the number of patients contributed to the
study are shown in Table 1.
Information Requested by Questionnaire
The information requested for each patient included patient
age and sex, presence of predisposing factors, use of adjuvant
therapies, and site of relapse, if any. Other information included
the date of surgery, Dukes’ stage, surgical outcome, and site of the
primary tumor. Tumor site was classified as follows: proximal
colon included cecum through to and including transverse colon
(Original OperationsDetails [OOD]-2 codes CP1, CP3), distal colon
included splenic flexure through to and including the descending
colon (OOD-2 code CP2), and rectal cancer group comprising the
sigmoid colon and rectum (OOD-2 code CP4). Other information
included the date of last follow-up or death (perioperative, cancer or
unrelated to cancer), tumor type (flat or polypoid), histologic grade
(well-differentiated [G1],moderately differentiated [G2], poorly dif-
ferentiated [G3]), lymphocyte infiltration (prominent, not promi-
nent), vascular invasion, mucinous status (0% to 50%,  50%),
lymphatic invasion, and regional lymph node involvement.
Information on the type of tissue was also requested (frozen
or paraffin embedded) as well as the control tissue used (normal
mucosa, blood, or other). Information on the methods used for
mutational analysis of the TP53 gene were also requested, includ-
ing polymerase chain reaction–single-stranded conformation
polymorphism (PCR-SSCP), PCR–denaturing gradient gel elec-
trophoresis (DGGE), PCR sequencing, or other.
Information on the type of TP53 gene mutation (point or
frameshift) and site ofmutation (codon, exon, functional domain,
or conserved area) was also requested. For tumors withmore than
one mutation, the data for each is included as a separate entry.
Where specific information was not available, this was entered in
the database as not available.
Patient Characteristics
This collaborative study included data from a total of 3,583
CRC patients (from 17 different countries) with information on
TP53 gene mutation status. Patients were divided into three
groups according to site of the primary tumor: 1,017 (28%) sites
were proximal colon, 426 (12%) were distal colon, and 2,031
(57%) were sigmoid colon and rectum. For another 109 (3%)
patients, it was not possible to establish the site of the original
tumor and hence these were not included in the analyses relating
to tumor site. Table 2 shows the clinicopathologic features of the
three patient groups classified according to site of tumor origin
and includes patient age and sex; tumor size, stage, and grade;
lymphatic and vascular invasion; and treatment with chemother-
apy for the Dukes’ C subgroup. Median follow-up times for pa-
tientswere 58months (range, 1 to 194months), 61months (range,
1 to 173 months), and 61months (range, 1 to 235 months) for the
proximal colon, distal colon, and rectal tumor groups, respec-
tively. Additional information on patient and tumor characteris-
tics from each of the contributing centers is shown in the
Appendix, Supplementary Table.
TP53 Mutation Screening Techniques
TP53 mutational analyses spanned exons 4 to 8. Exon 4 was
screened in 1,880 patients (53%). For mutational analysis, 14
groups used frozen material for a total of 1,191 specimens (34%),
and nine groups used paraffin-embedded specimens for 1,878
specimens (52%). Fresh tissue was used for 63 specimens (1.7%),
whereas the storage method was not specified for 514 specimens
(14%). Normal mucosa was used as the non-neoplastic control in
90% (3,243 of 3,583) of patients. A total of 2,397 patients were
screened by PCR-SSCP followed by sequencing, 158 patients were
screened by PCR-DGGE followed by sequencing, 281 patients
were screened directly by DNA sequencing, 114 patients were
screened by SSCP alone, and 454 patients were screened by
temperature-gradient gel electrophoresis or DGGE alone. No in-
formation on the TP53 mutation screening technique was pro-
vided for 179 patients.
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Definition of TP53 Mutation Types
The analyses involved consideration of any TP53 muta-
tion, mutations specific to exons 4 to 8, and those in regions
coding for the main functional and structural domains of the
protein. These included the L2 loop (codons 163 to 195), L3
loop (codons 236 to 251), LSH motif (codons 271 to 286) as
well as the highly conserved areas II (codons 117 to 142), III
(codons 171 to 181), IV (codons 234 to 258), and V (codons 270
to 286).34 Mutations in the hotspot codons were also examined
(codons 175, 196, 213, 245, 248, 249, 273, and 282), as well as
those in the denaturant codons known to have a direct effect on
TP53 stability (codons 143, 175, 245, 249, and 282), those in
zinc-binding codons (codons 176, 179, 238, and 242), those
involved with DNA interaction (codons 120, 241, 248, 273, 276,
277, 280, 281, and 283), and those involved in direct DNA
contact (codons 248 and 282).5,34 Analysis of point mutations
(missense and nonsense), frameshift mutations (insertions and
deletions), and transitions and transversions was performed.
Finally, analysis of mutations that affect the following classes of
amino acids was performed: polar neutral, apolar neutral, ba-
sic, and acid, together with the type of amino acid change
according to the lateral group.
Statistical Analysis
Statistical analyses were performed separately for each of
the three subgroups of patients classified according to the site of
tumor origin. Associations between TP53 mutations (any or
specific) and clinicopathologic variables were evaluated by the
2 test with Yates correction, where appropriate. The relation-
ship between different prognostic variables and overall survival
(OS) was assessed univariately by the Kaplan-Meier method.
Patients with no follow-up details (n  708) were excluded
from the OS analyses. Survival time was calculated from the
date of surgery to the date of death (cancer-related causes) or
last follow-up, with times censored for patients who died as a
result of causes unrelated to CRC or perioperatively. Significant
differences between survival curves were evaluated by the log-
rank and Wilcoxon tests, or a test for trend where appropriate.
In view of the multiple statistical analyses performed, only
values where P  .01 were considered significant. Multivariate
analysis was carried out by means of the Cox proportional
hazards model, using a backward procedure.35 Only the signif-
icant variables in univariate analysis were considered in the Cox
model. All P values were two sided.
Table 1. Groups Included in the TP53-CRC International Collaborative Study
Author Country
Total No.
of
Patients
TP53 Mutation
Frequency
Patients for
Survival
Analyses Median
Follow-Up
(months)
Patients for
Clinical and
Pathologic
Associations
Patients
With
Unknown
Tumor
SiteNo. % No. %
Iacopetta et al14 Australia 1,135 406 36 1,090 97 82 1,121 14
Kandioler et al15 Austria 74 53 71 71 97 35 73 1
Lung et al16 China 99 35 35 16 16 9 97 2
Yuen et al17 China 67 29 43 66 98 89 67 0
Crapez et al† France 91 33 36 87 96 48 91 0
Leahy et al18 Ireland 66 27 41 66 100 121 66 0
Chieco-Bianchi et al19 Italy 335 139 41 0 NA 329 6
Giaretti et al20 Italy 60 35 58 13 23 31 56 4
Ricevuto et al† Italy 44 18 41 43 100 89 43 1
Russo et al9 Italy 160 68 43 160 100 71 160 0
Miyaki21 Japan 58 34 59 0 45 NA 57 1
Onda22 Japan 45 27 60 100 98 45 0
Kampman23 Netherlands 184 57 31 140 81 55 172 12
Lothe et al24 Norway 221 100 45 218 99 63 221 0
Guzinska et al† Poland 47 21 45 43 91 34 47 0
Ostrowski et al25 Poland 50 23 46 48 96 58 50 0
Capella et al26 Spain 163 81 50 161 99 18 163 0
Lonnroth/Lundholm K et al27 Sweden 98 37 38 93 99 103 94 4
Sun et al28 Sweden 75 41 55 71 94 176 73 0
Bouzourene et al29 Switzerland 123 39 32 122 99 64 123 0
Hsieh et al30 Taiwan 182 57 31 180 99 96 182 0
Smith13 Thailand 53 NA 0 NA 0 53
Allan-Mersh et al31 United Kingdom 20 Not assessable‡ 11 100 34 11 9
Royds et al32 United Kingdom 19 16 84 19 100 52 19 0
Bosari and Silverman33 United States 114 65 57 112 98 75 114 0
Total 3,583 2,875 80 3,474 109
Abbreviation: NA, not available.
No information given on primary site of tumors.
†Unpublished data.
‡This group supplied information only for patients with p53 mutation.
TP53-CRC International Collaborative Study
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Table 2. Patient Characteristics According to Site of the Primary CRC
Characteristic
Proximal Colon Distal Colon Rectum
PNo. % No. % No. %
Total No. 1,017 426 2,031
Age, years
 50 82 8 42 10 264 13
50-75 664 66 299 71 1,364 67
 75 265 26 82 19 397 20  .001
Mean 67.4 64.9 64.5
SD 11.8 11.8 12.7
Range 21-93 19-91 20-99
Sex
Male 503 49 218 51 1,153 57
Female 512 51 207 49 877 43  .001
Size, cm
 5 147 49 92 69 509 72
 5 153 51 41 31 197 28  .001
Type
Flat 24 15 21 23 83 19
Polypoid 131 85 72 77 360 81 NS
Dukes’ stage
A 64 6 38 9 266 13
B 391 39 170 40 650 32
C 470 46 163 38 950 47
D 90 9 55 13 154 8  .001
Regional lymph nodes
N0 419 48 209 54 802 49
N1 253 29 106 28 504 31
N2/N3 195 23 68 18 330 20 NS
Histologic grade
Well-differentiated (G1) 139 14 79 19 283 15
Moderately differentiated (G2) 605 62 290 70 1,398 72
Poorly differentiated (G3) 236 24 44 11 255 13  .001
Lymphatic invasion
Present 115 48 54 47 249 46
None 127 52 62 53 292 54 NS
Lymphocyte infiltration
Prominent 43 24 48 53 124 37
Not prominent 133 76 43 47 212 63  .001
Vascular invasion
Present 51 26 12 13 133 26
None 147 74 82 87 382 74 NS
Mucinous status
Not mucinous tumors (0%-50%) 229 84 103 88 583 93
Mucinous tumors ( 50%) 44 16 14 12 42 7 .022
Surgical resection
Apparently curative 817 92 271 92 1,727 94
No resection/residual tumor 69 8 23 8 119 6 NS
Chemotherapy treatment†
Total 470 163 950
Yes 140 35 43 37 284 34
No 260 65 72 63 538 66 NS
NOTE. In 109 patients, the site of primary CRC was unknown. Age was not known for 15 patients, sex was not known for 4 patients, size was not known
for 2,335 patients, type was not known for 2,783 patients, Dukes’ stage was not known for 13 patients, regional lymph nodes were not known for 588
patients, histologic grade was not known for 145 patients, lymphatic invasion was not known for 2,575 patients, lymphocyte infiltration was not known for
2,871 patients, vascular invasion was not known for 2,667 patients, mucinous status was not known for 1,789 patients, surgical resection was not known
for 448 patients, and chemotherapy treatment in Dukes’ C was not known for 246 patients.
Abbreviation: CRC, colorectal cancer.
The percentage of clinicopathologic variables was calculated only for known patients.
†Dukes’ C patients only; chemotherapy treatment was with or without radiotherapy in rectal cancer patients.
Russo et al
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RESULTS
The 25 different groups that contributed data to this study
on TP53 mutations in CRC are listed in Table 1. Raw data
from individual studies are listed in the Appendix, Supple-
mentary Table.
Clinicopathologic Results
Clinicopathologic data were analyzed according to the
site of tumor origin in the large bowel (Table 2). In line with
previous studies on CRC, rectal cancer patients were
younger and more often male compared with proximal
cancer patients. Rectal tumors were also smaller compared
with proximal colon tumors. Proximal cancers were more
often poorly differentiated and mucinous but showed less
lymphocyte infiltration compared with rectal cancers.
No site-related differences were apparent for the fre-
quency of nodal involvement, vascular invasion, or the
use of chemotherapy.
Using proximal colon cancer as the reference group,
patients with distal colon cancer showed marginally better
OS (relative risk [RR] 0.82; 95%CI 0.68 to 1.00; P .05).
No significant difference inOSwas observed between prox-
imal colon and rectal tumor groups. The OS of patient
subgroups classified according to the site of tumor origin in
the large bowel is listed in Table 3. For each tumor site, only
the clinical features that show significant prognostic value
are shown. As expected, advanced Dukes’ stage, nodal in-
volvement, poor histologic grade, lymphatic invasion, and
noncurative resections were all associated with significantly
worse survival.
Relationship Between TP53 Mutations and
Clinicopathologic Features
The overall frequency of TP53mutation in this CRC
series was 42% (1,449 of 3,474). A significantly higher
frequency of mutations (P  .001) was found in distal
colon and rectal tumors (both groups, 45%) compared
with proximal tumors (34%; Table 4). TP53 mutations
were associated with lymphatic invasion in proximal
tumors and showed trends for association with ad-
vanced Dukes’ stage (all sites) and with lymphatic (rectal
Table 3. Overall Survival of the CRC Patients According to Clinicopathologic Variables (univariate analyses)
Clinicopathologic Variable
Proximal Colon Distal Colon Rectum
No. OR 95% CI P No. OR 95% CI P No. OR 95% CI P
Total No. of patients 853 282 1,740
Age, years
 50 65 1.18 0.82 to 1.70 NS 188 0.90 0.49 to 1.65 NS 227 0.95 0.77 to 1.18 NS
50-75 561 1.00 28 1.00 1,164 1.00
 75 225 1.33 1.09 to 1.63 .006 64 1.40 0.94 to 2.08 NS 346 1.62 1.39 to 1.89 < .001
Sex
Male 413 1.00 132 1.00 972 1.00
Female 440 1.05 0.87 to 1.27 NS 149 1.58 1.11 to 2.26 .012 768 0.85 0.74 to 0.97 .013
Dukes’stage
A 44 1.00 23 1.00 201 1.00
B 322 1.09 0.66 to 1.81 NS 119 1.43 0.61 to 3.38 NS 549 1.29 0.97 to 1.70 .078
C 423 2.71 1.65 to 4.44 < .001 115 2.75 1.19 to 6.38 .018 867 2.60 2.00 to 3.37 < .001
D 62 7.15 4.12 to 12.4 < .001 25 7.97 3.20 to 19.8 < .001 113 6.61 4.70 to 9.11 < .001
Regional lymph nodes
N0 329 1.00 135 1.00 632 1.00
N1 222 2.37 1.83 to 3.07 < .001 65 1.99 1.26 to 3.14 .003 443 1.86 1.56 to 2.23 < .001
N2/N3 156 3.70 2.83 to 4.85 < .001 39 2.66 163 to 4.35 < .001 282 2.82 2.33 to 3.41 < .001
Histologic grade
Well-differentiated (G1) 108 1.00 47 1.00 214 1.00
Moderately differentiated (G2) 516 1.05 0.79 to 1.41 NS 189 1.19 0.72 to 1.96 NS 1217 1.32 1.07 to 1.64 .011
Poorly differentiated (G3) 201 1.57 1.14 to 2.15 .006 36 2.50 1.34 to 4.67 .004 228 2.06 1.60 to 2.67 < .001
Lymphatic invasion
None 110 1.00 55 1.00 254 1.00
Present 99 2.27 1.39 to 3.70 .001 49 3.12 1.67 to 5.88 < .001 210 2.12 1.56 to 2.86 < .001
Mucinous status
Not mucinous (0%-50%) 199 1.00 91 1.00 505 1.00
Mucinous ( 50%) 41 1.76 1.12 to 2.77 .014 13 0.96 0.41 to 2.24 NS 38 1.51 0.98 to 2.31 .061
Surgical resection
Apparently curative 765 1.00 255 1.00 1,608 1.00
No resection/residual tumor 62 4.04 3.00 to 5.42 < .001 20 6.17 3.57 to 10.7 < .001 106 4.48 3.57 to 5.62 < .001
NOTE. Significant results are shown in bold type.
Abbreviations: OR, odds ratio; NS, not significant.
The reference group value is 1.00.
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tumors) or vascular invasion (distal and rectal tumors;
Table 4). None of the other clinicopathologic features
(age, sex, size, or grade) showed significant associations
with TP53 mutation frequency. Frameshift mutations
were associated with lymphatic invasion in proximal
tumors (P  .01; data not shown), and in rectal tumors
frameshift mutations showed trends for association with
advanced Dukes’ stage, and lymphatic and vascular inva-
sion (P  .05; data not shown).
Mutation Analysis of the TP53 Gene
The different types of TP53 mutations in this CRC
cohort are shown in Table 5. Three hundred fifty (34%) of
the 1,017 patients with a proximal colon cancer had TP53
mutations, with 28 showing more than one mutation. Of
these, seven had two mutations in one exon, 18 had two
mutations in two exons, and three had three mutations,
producing a total of 381mutations identified. One hundred
ninety-one (45%) of the 426 patients with distal colon
cancer had TP53 mutations, with 11 showing more then
one mutation. Of these, seven had two mutations in one
exon, three had two mutations in two exons, and one had
three mutations in two different exons, for a total of 203
mutations identified. Finally, 908 (45%) of the 2,031 pa-
tients with rectal cancer had a mutation in TP53, with 46
patients showing more than one mutation. Of these, 14
patients had two mutations in one exon, 29 had two muta-
tions in two exons, and three had three mutations in two
different exons, producing a total of 957 mutations identi-
fied. A remarkably similar profile for the type of TP53
mutation was observed for tumors from the three different
sites, with no significant differences between sites observed
for the frequency of any individual TP53 mutation type
examined (Table 5).
TP53 Mutations and Clinical Outcome
TP53 mutations in the overall CRC cohort or in the
three different tumor site groups did not show significant
prognostic value (Table 6). Investigation of different
types of TP53 mutations revealed some interesting asso-
ciations, however, particularly for distal colon tumors. In
this group, worse outcome compared with tumors with
wild-type TP53 was observed for mutations in the LSH
region, denaturing mutations, multiple mutations, or
mutations yielding the same amino acid side group or an
amino acid loss (Table 6). For proximal colon tumors,
only TP53 mutations in exon 5 were significantly associ-
ated with worse survival; for rectal tumors, only those
giving rise to an amino acid loss were significantly asso-
ciated with worse survival. In multivariate analysis ad-
justed for Dukes’ stage, nodal status, histologic grade,
and lymphatic invasion, only TP53 mutation associated
with an amino acid loss in distal colon tumors was an
independent factor for worse survival (RR  2.52; 95%
CI, 1.28 to 4.93; P  .007). A trend toward statistical
significance for worse outcome was also observed for
exon 5 mutations in proximal colon tumors (RR 1.36;
95% CI, 1.03 to 1.79; P  .03). Adjustment for study
center revealed no significant differences in the odds
ratio for survival for either TP53 mutation or Dukes’
stage (results not shown).
TP53 Mutations and Adjuvant Treatment
The predictive significance ofTP53mutation inDukes’
C patients treated with or without adjuvant chemotherapy
is listed in Table 7. For patients with wild-type TP53, those
treated with chemotherapy showed significantly better sur-
vival in proximal colon and rectal tumor groups, whereas
a trend toward statistical significance (P  .022) was ob-
served for the distal colon tumors. For patients with
Table 4. Associations Between TP53 Mutation and Clinicopathologic Features According to Site of the Primary CRC
Clinicopathologic
Variable
Proximal Colon Distal Colon Rectum
TP53
Mutation % P TP53 Mutation % P TP53 Mutation % P
All patients 350 of 1,017 34 191 of 426 45 908 of 2031 45
Dukes’ stage
A 15 of 64 23 11 of 38 29 109 of 266 41
B 133 of 391 34 72 of 170 42 288 of 650 44
C 163 of 470 35 79 of 163 49 423 of 950 45
D 38 of 90 42  .05 29 of 55 53  .05 84 of 154 55  .05
Lymphatic invasion
None 32 of 127 25 22 of 62 35 136 of 292 47
Present 49 of 115 43  .01 27 of 54 50 NS 140 of 249 56  .05
Vascular invasion
None 18 of 147 12 36 of 82 44 182 of 382 48
Present 22 of 51 43 NS 9 of 12 75  .05 79 of 133 59  .05
Abbreviations: CRC, colorectal cancer; NS, not significant.
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Table 5. Frequency of TP53 Mutations in CRC According to Tumor Site and Type of Mutation
TP53 Mutation
Total Proximal Colon Distal Colon Rectum
No. % No. % No. % No. %
Any mutation 1,541 381 203 957
Mutations in functional domains
L2 249 20 53 19 26 16 170 22
L3 318 26 64 22 45 29 209 27
LSH 251 21 57 20 39 24 155 20
Outside L2-L3-LSH 396 33 113 39 50 31 233 31
Exons
4 44 3 15 4 3 2 26 3
5 454 30 121 32 55 27 278 29
6 203 13 56 15 20 10 127 13
7 438 29 93 24 62 31 283 30
8 350 22 82 21 54 27 214 23
Other 41 3 14 4 7 3 20 2
Areas
Conserved 845 69 193 67 115 72 537 70
Nonconserved 372 31 94 33 45 28 233 30
Codons
175 139 9 30 8 19 9 90 9
196 11 1 1 0 0 0 10 1
213 42 3 17 4 6 3 19 2
245 68 4 9 2 5 2 54 6
248 138 9 31 8 20 10 87 9
249 21 1 2 0 7 3 12 1
273 116 8 28 7 16 8 72 8
282 76 5 15 4 13 6 48 5
All hot-spot 609 40 131 34 86 42 392 41
All denaturing 305 20 56 15 45 22 204 21
All directly contact DNA 275 18 64 17 39 19 172 18
All bind zinc 36 2 9 2 4 2 23 2
All severe contact 214 14 46 12 33 16 135 14
Other 548 36 138 36 65 32 345 36
Mutations distribution
One mutation in one exon 1,364 94 322 92 180 94 862 94
Two mutations in one exon 28 2 7 2 7 4 15 2
Two mutations in two exons 50 4 18 5 3 2 28 3
Three mutations 7 0 3 1 1 0 3 1
Amino acid change
Same side group 478 40 105 37 59 38 314 41
Different side group 507 42 125 44 71 45 311 41
Amino acid loss 217 18 52 18 27 17 138 12
Amino acid pH
Basic 632 53 147 52 95 65 390 51
Acid 40 3 15 5 5 3 20 2
Polar neutral 321 27 70 25 33 21 218 29
Apolar neutral 209 17 50 18 24 15 135 18
Type of mutation
Frameshift 140 12 34 12 19 12 87 11
Point mutation† 1,071 88 250 88 139 88 682 89
Transition 855 80 199 80 114 82 542 80
Transversion 216 20 51 20 25 18 140 20
NOTE. Mutations could not be ascribed to functional groups in 246 patients, to exons in 11 patients, to conserved areas in 324 patients, to codons in 324
patients, to amino acid change in 339 patients, to amino acid pH in 339 patients, and to type of mutation in 330 patients.
Deletion plus insertion.
†Missense plus nonsense.
TP53-CRC International Collaborative Study
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mutated TP53, better survival with chemotherapy was only
observed for the proximal colon tumor group (P  .001).
TP53 mutation had no predictive value within Dukes’ C
patient groups treated by surgery alone or within those
treated by surgery and chemotherapy (results not shown).
DISCUSSION
Although a large number of research groups have studied
TP53 gene mutations in CRC, controversy still exists re-
garding the prognostic significance of this alteration.36 The
likely explanation for this is the insufficient statistical power
of the various individual studies. Another reason might be
that most studies have considered the prognostic signifi-
cance of all mutations combined. These are usually within
the conserved region spanning exons 5 to 8 (codons 130 to
286). However, several authors have suggested that muta-
tions that affect certain functionally important regions of
the TP53 protein may have a stronger prognostic impact.7,9
Another reason for discordance in the literaturemay be that
CRC has often been considered a single disease. There is
increasing evidence to suggest that different pathways of
tumor progression exist within different anatomic regions
of the colon,2,37,38 and hence, TP53 mutations may have a
different prognostic impact depending on the site of tumor
origin. Finally, the prognostic significance of TP53 muta-
tion may also depend on the adjuvant treatment status of
the patient group being studied.
The TP53-CRC International Collaborative Study is
the largest study to date on the prognostic value of TP53
Table 6. Prognostic Significance (univariate overall survival analysis) of Different Types of TP53 Mutation According to Tumor Site
Type of TP53 Mutation
Proximal Colon Distal Colon Rectum†
No. OR 95% CI P No. OR 95% CI P No. OR 95% CI P
Total 853 282 1,740
TP53 mutations
WT 563 1.00 164 1.00 968 1.00
Any mutations 290 1.19 0.98 to 1.44 .073 118 1.29 0.91 to 1.83 NS 772 0.97 0.85 to 1.11 NS
Functional domains
WT 563 1.00 164 1.00 968 1.00
Mutation in L2 76 1.18 0.85 to 1.63 NS 21 0.96 0.44 to 2.10 NS 167 1.09 0.87 to 1.37 NS
Mutation in L3 38 1.50 0.99 to 2.27 .058 15 1.29 0.62 to 2.70 NS 141 0.88 0.68 to 1.13 NS
Mutation in LSH 51 1.08 0.72 to 1.61 NS 20 1.87 1.05 to 3.33 .033 161 0.95 0.76 to 1.20 NS
Outside L2-L3-LSH 46 0.80 0.51 to 1.26 NS 23 1.26 0.67 to 2.38 NS 136 0.88 0.69 to 1.13 NS
TP53 Exons
WT 563 1.00 164 1.00 968 1.00
Exon 5 91 1.47 1.11 to 1.93 .007 31 1.42 0.84 to 2.38 NS 224 0.98 0.80 to 1.19 NS
Other exons (4, 6, 7, 8) 199 1.07 0.86 to 1.34 NS 86 1.24 0.84 to 1.83 NS 540 0.97 0.83 to 1.12 NS
Site of TP53 mutations
WT 563 1.00 164 1.00 968 1.00
Denaturing 47 1.16 0.76 to 1.76 NS 21 2.22 1.27 to 3.90 .005 177 0.94 0.75 to 1.18 NS
Other mutations 163 1.10 0.86 to 1.40 NS 58 1.83 0.69 to 1.72 NS 439 0.96 0.82 to 1.12 NS
TP53 mutation distribution
WT 563 1.00 164 1.00 968 1.00
One mutation in one exon 264 1.19 0.98 to 1.46 .082 107 1.18 0.82 to 1.69 NS 731 0.98 0.86 to 1.12 NS
Two mutations in one exon 7 0.96 0.39 to 2.32 NS 7 3.56 1.63 to 7.78 .001 14 1.10 0.55 to 2.22 NS
Two mutations in two exons 19 1.29 0.74 to 2.26 NS 4 1.52 0.37 to 6.19 NS 27 0.75 0.44 to 1.28 NS
Amino acid change
WT 563 1.00 164 1.00 968 1.00
Same side group 70 0.99 0.69 to 1.41 NS 28 1.77 1.04 to 3.01 .035 243 0.92 0.75 to 1.12 NS
Different side group 95 1.20 0.89 to 1.62 NS 36 0.77 0.42 to 1.42 NS 248 0.87 0.71 to 1.06 NS
Amino acid loss 43 1.12 0.74 to 1.71 NS 14 2.35 1.21 to 4.59 0.012 111 1.30 1.01 to 1.67 0.045
Amino acid type
WT 563 1.00 164 1.00 968 1.00
Polar neutral 55 1.25 0.87 to 1.79 NS 22 2.03 1.14 to 3.61 .016 180 1.00 0.81 to 1.24 NS
Other type (apolar neutral, basic, acid) 151 1.04 0.81 to 1.34 NS 55 1.11 4.89 to 1.76 NS 422 0.93 0.79 to 1.09 NS
NOTE. Significant results are shown in bold type. Reference group was WT (risk ratio, 1.00).
Abbreviations: OR, odds ratio; WT, wild type; NS, not significant.
Mutations could not be ascribed to functional groups in 39 patients, to site of mutations in 39 patients, to amino acid change in 40 patients, and to amino
acid type in 41 patients.
†Mutations could not be ascribed to amino acid change in 170 patients.
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mutations in colorectal cancer. The large sample size has
allowed investigation of factors that might influence the
prognostic significance of this genetic alteration, includ-
ing tumor site, type of mutation, and adjuvant therapy
status. In accordance with other reports,12,37 distal colon
and rectal tumors were found to have significantly more
mutations than proximal colon tumors (45%, 45%, and
34%, respectively; Table 4). Other genetic and epigenetic
alterations also differ in frequency according to tumor
site and include microsatellite instability, the cytosine
phosphate guanine island methylator phenotype, aneu-
ploidy, and loss of heterozygosity.39,40 In agreement with
the proposal that TP53 mutation occurs late in tumor
progression,11 the frequency of this alteration increased
with advancing tumor stage (Table 4).
Regarding other clinical features of CRC, TP53 muta-
tions were associated with lymphatic invasion in proximal
colon and showed trends toward statistical significance for
associations with lymphatic (rectal tumors) and vascular
invasion (distal and rectal tumors). We found no associa-
tions between specific TP53 mutations and clinicopatho-
logic variables other than that frameshift mutations were
strongly associated with lymphatic invasion in the proximal
colon. These data suggest that TP53 frameshift mutations
might be a useful marker of more advanced and aggressive
cancer arising at this site.
Our study also demonstrated some interesting trends
(P .05) for associations in rectal cancer among any TP53
mutation or frameshift TP53 mutation and advanced
Dukes’ stage, lymphatic invasion, and vascular invasion.
This might be explained by different biologic effects of
mutagenic agents (eg, alkylating agents) depending on site
in the large bowel. There have been reports that certain
dietary-associated risks are strongest in the distal colon.41 In
the rectum, the presence of these mutagenic agents for a
longer periodmight havemore pronounced effects onTP53
mutation and cause the observed associations with more
aggressive clinicopathologic features. At present there are
no other reports enabling confirmation of our hypothesis;
no studies have been conducted on the effect of these mu-
tagenic agents on rectal cancer and on specific TP53muta-
tions at this site.
As expected, the conventional clinicopathologic vari-
ables (Dukes’ stage, histological grade, mucinous status,
node status, lymphatic invasion, tumor type, and surgical
resection) each showed prognostic value in this cohort of
CRC patients (Table 3). Small deletions of the TP53 gene
causing amino acid loss were also found to be an indepen-
dent prognostic factor in distal colon tumors in our study
(Table 6). The prognostic significance of this type of TP53
mutation has not been reported previously for any tumor
type. It is generally recognized that chromosomal region
17p13.1 containing theTP53 gene is subjected frequently to
allelic deletions in human CRC.42-45
Kern et al43 have found that analysis of allelic deletions
may be an efficient means to identify subsets of CRC pa-
tients at higher risk for distant metastases and cancer-
related death, especially with regard to left-sided tumors.
Not all studies have been able to confirm the prognostic
significance of 17p allelic loss, however.45 The current find-
ings suggest that small deletions in the TP53 gene in distal
colon tumors leading to loss of amino acids might provide
more valuable prognostic information than allelic loss. In
addition, TP53mutations in exon 5 showed a trend toward
statistical significance when OS was considered in patients
with proximal colon tumors (Table 6). Other authors have
reported previously that mutations in specific TP53 exons
are factors for poor prognosis in colorectal and lung can-
cers6,46 and Vega et al47 have reported that mutations in
exon 5 are associated with shortened survival in non–small-
cell lung cancer.
None of the differentTP53mutation types evaluated in
this study showed independent prognostic value in rectal
tumors. The different behavior of rectal tumors compared
with tumors from other anatomic regions of the colon may
have beenmasked in previous studies by the grouping of all
colorectal tumors together. Furthermore, in rectal cancers
the quality of surgery is an important factor in outcome,
Table 7. Overall Survival of Dukes’ C Patients Treated With or Without Chemotherapy and According to TP53 Mutation Status (univariate analyses)
Treatment
Proximal Colon Distal Colon Rectum
No. RR 95% CI P No. RR 95% CI P No. RR 95% CI P
Wild-type TP53
No chemotherapy 164 1.00 39 1.00 305 1.00
Chemotherapy 98 0.61 0.43 to 0.87 .006 23 0.35 0.14 to 0.86 .022 163 0.55 0.43 to 0.71 < .001
Mutated TP53
No chemotherapy 96 1.00 30 1.00 233 1.00
Chemotherapy 42 0.39 0.22 to 0.68 < .001 20 1.15 0.49 to 2.70 NS 121 0.78 0.57 to 1.06 NS
NOTE. Significant results are shown in bold type.
Abbreviations: RR, relative risk; NS, not significant.
Chemotherapy was or was not associated with radiotherapy in rectal cancer patients.
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particularly whether total mesorectal excision is carried out,
andhence it will not be possible to clarify the role of individual
prognostic factors at this site until standardized surgery is
performed.48 Until recently, there have been few studies deal-
ing with biologic differences between tumors of the colon and
those of the rectum,48 and few authors have investigated the
prognostic role of TP53 in rectal carcinoma. The present re-
sults agree with some previous reports49,50 but do not support
those of a recent study by Rebischung et al,51 in which they
state that TP53 status is an independent prognostic factor of
survival in rectal carcinoma.
One of the most important clinical applications of this
study involves the possibility for improved selection of pa-
tients to receive chemotherapy. Molecular profiling may
serve as a complement to established morphologic param-
eters for the improved identification of chemotherapy-
responsive patients. The response to most drugs, including
FU, is complex and therefore unlikely to be explained by
any single genetic alteration. However, in vitro studies have
shown that disruption ofTP53 causes colorectal cancer cells to
bemore resistant to theapoptotic effectsofFU.52 Inagreement
with these observations, we found that colorectal cancer pa-
tients with wild-type TP53 have significantly better survival
when treatedwith chemotherapy comparedwith those treated
with surgery alone, regardless of tumor site (Table 7). In con-
trast, forpatientswithmutatedTP53, only thosewithproximal
colon cancers showed significantly better survival when
treated with chemotherapy compared with those treated by
surgery alone.These results shouldbe interpretedwith caution
because of the nonrandomized nature of the chemotherapy
treatment. In addition, we grouped all FU-based treatment
regimens into one group, even though TP53 mutation may
show different predictive values according to the exact type of
treatment used. Nevertheless, our results suggest that use of
chemotherapy can influence survival depending onTP53mu-
tation status; thismay also be dependent on tumor site. Previ-
ous studies showing site-relateddifferences in the frequencyof
TP53 mutations and other genetic or epigenetic alterations
have also suggested that these findings could translate into
differential survival benefits from chemotherapy.37,53
This study also investigated the effect of TP53mutations
in patients with Dukes’ stage C rectal cancer who underwent
adjuvant chemotherapywith orwithout radiotherapy. In vitro
studies have demonstrated that cells with TP53 mutations
show reduced radiation-induced growth arrest and increased
radioresistance,54,55 although ionizing radiation may induce
apoptosis through TP53-independent mechanisms.56 Our re-
sults and other studies57,58 show that rectal tumor patients
with wild-type TP53 derived significant survival benefit
from the use of FU-based chemotherapy, whether combined
with radiotherapy or not. Because the current studywas retro-
spective, not all groups that contributed data were able to
provide information about treatment modality. Moreover, in
the period before 1991, few patients received adjuvant treat-
ment. These results should therefore be considered as prelim-
inary only.
In conclusion, the results of the TP53-CRC International
Collaborative Study demonstrate the importance of primary
tumor site when analyzing the prognostic value of TP53mu-
tations in CRC. In addition, different types of TP53mutation
might play a pivotal role in determining the biologic behavior
of CRC from different sites and hence the prognosis of pa-
tients. This meta-analysis found evidence for interesting tu-
mor site differences in the predictive value of TP53mutation
for survival benefit from FU chemotherapy. We believe that
additional trials on the prognostic value ofTP53mutation are
probably not warranted in view of the relatively weak associa-
tions observed here (Table 6) and the emergence of newer
technologies that investigate genome-wide markers.59 Addi-
tional trials to evaluate the predictive significance of TP53
mutation are justified, however, in light of the present findings
(Table 7). These would require sufficient patient numbers to
allow multivariate analysis, and preferably would involve ho-
mogenous treatment regimens and standardized TP53muta-
tion screening techniques.
■ ■ ■
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Appendix: Supplementary Table. Patient and Tumor Characteristics From Individual Study Centers That Contributed Data to the
TP53-CRC Meta-Analysis
Characteristic No. Proximal Colon No. Distal Colon No. Rectum
Iacopetta et al14: Australia
Total 342 99 680
Age, years
 50 22 9 78
50-75 215 65 424
 75 105 25 178
Sex
Male 150 48 353
Female 192 51 327
Dukes’ stage
A 5 2 11
B 83 21 167
C 247 75 493
D 7 1 9
Histologic grade
G1 32 17 82
G2 211 63 445
G3 95 17 115
Chemotherapy treatment (Dukes’ C stage)
Yes 77 27 149
No 170 48 344
Kandioler et al15: Austria
Total 10 1 62
Age, years
 50 0 0 12
50-75 9 1 45
 75 1 0 4
Sex
Male 6 1 39
Female 4 0 23
Dukes’ stage
A 0 0 13
B 0 0 18
C 10 1 26
D 0 0 4
Histologic grade
G1 32 0 1
G2 211 0 33
G3 95 0 17
Chemotherapy treatment (Dukes’ C stage)
Yes 9 1 16
No 1 0 10
Lung et al16: China
Total 23 10 64
Age, years
 50 4 0 15
50-75 15 6 34
 75 4 4 15
Sex
Male 15 4 38
Female 8 6 26
Dukes’ stage
A 1 0 3
B 14 8 33
C 5 1 17
D 3 1 11
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Appendix: Supplementary Table. Patient and Tumor Characteristics From Individual Study Centers That Contributed Data to the
TP53-CRC Meta-Analysis (continued)
Characteristic No. Proximal Colon No. Distal Colon No. Rectum
Histologic grade
G1 2 2 9
G2 15 6 50
G3 5 1 1
Chemotherapy treatment (Dukes’ C stage)
Yes 0 0 1
No 5 1 16
Yuen et al17: China
Total 6 4 57
Age, years
 50 2 1 17
50-75 3 1 21
 75 1 2 19
Sex
Male 4 3 32
Female 2 1 25
Dukes’ stage
A 0 1 13
B 2 1 19
C 2 2 21
D 2 0 4
Histologic grade
G1 1 1 10
G2 4 2 44
G3 0 1 3
Chemotherapy treatment (Dukes’ C stage)
Yes 0 0 3
No 2 2 18
Crapez et al: France
Total 30 10 51
Age, years
 50 2 4 4
50-75 12 4 31
 75 16 2 16
Sex
Male 11 6 23
Female 19 4 28
Dukes’ stage
A 2 2 13
B 9 5 16
C 8 0 10
D 11 3 12
Histologic grade
G1 11 5 32
G2 13 4 17
G3 5 1 1
Chemotherapy treatment (Dukes’ C stage)
Yes 5 0 5
No 3 0 5
Leahy et al18: Ireland
Total 17 2 47
Age, years
 50 3 0 2
50-75 3 1 37
 75 11 1 8
Sex
Male 0 1 32
Female 6 1 15
Dukes’ stage
A 2 0 12
B 6 1 16
(continued on following page)
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Appendix: Supplementary Table. Patient and Tumor Characteristics From Individual Study Centers That Contributed Data to the
TP53-CRC Meta-Analysis (continued)
Characteristic No. Proximal Colon No. Distal Colon No. Rectum
C 9 1 19
D 0 0 0
Histologic grade
G1 0 0 0
G2 12 2 42
G3 5 0 5
Chemotherapy treatment (Dukes’ C stage)
Yes 0 0 0
No 9 1 19
Chieco-Bianchi et al19: Italy
Total 87 119 123
Age, years
 50 7 13 19
50-75 55 94 87
 75 24 12 17
Sex
Male 48 75 81
Female 39 44 42
Dukes’ stage
A 12 13 33
B 32 40 37
C 23 37 24
D 20 29 29
Histologic grade
G1 14 28 25
G2 50 86 80
G3 18 3 14
Chemotherapy treatment (Dukes’ C stage)
Yes 0 0 0
No 0 0 0
Giaretti et al20: Italy
Total 19 7 30
Age, years
 50 2 0 3
50-75 10 2 20
 75 2 2 2
Sex
Male 8 3 16
Female 9 3 13
Dukes’ stage
A 2 0 10
B 11 3 7
C 6 4 12
D 0 0 0
Histologic grade
G1 1 2 5
G2 15 4 17
G3 1 1 4
Chemotherapy treatment (Dukes’ C stage)
Yes 0 0 0
No 0 0 0
Ricevuto et al: Italy
Total 15 6 22
Age, years
 50 1 0 3
50-75 13 6 19
 75 1 0 0
Sex
Male 8 4 14
Female 7 2 8
(continued on following page)
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Appendix: Supplementary Table. Patient and Tumor Characteristics From Individual Study Centers That Contributed Data to the
TP53-CRC Meta-Analysis (continued)
Characteristic No. Proximal Colon No. Distal Colon No. Rectum
Dukes’ stage
A 3 0 5
B 5 4 9
C 5 2 6
D 2 0 1
Histologic grade
G1 1 1 2
G2 12 4 17
G3 2 0 1
Chemotherapy treatment (Dukes’ C stage)
Yes 3 2 5
No 2 0 1
Russo et al9: Italy
Total 31 52 77
Age, years
 50 2 3 9
50-75 20 39 52
 75 9 10 16
Sex
Male 12 20 44
Female 19 32 33
Dukes’ stage
A 6 11 23
B 11 15 25
C 10 13 18
D 4 13 11
Histologic grade
G1 21 10 10
G2 7 37 46
G3 0 5 21
Chemotherapy treatment (Dukes’ C stage)
Yes 5 4 4
No 5 9 14
Miyachi et al21: Japan
Total 14 4 39
Age, years
 50 2 0 3
50-75 9 3 30
 75 3 1 6
Sex
Male 10 1 22
Female 4 3 17
Dukes’ stage
A 4 0 12
B 7 1 11
C 3 3 16
D 0 0 0
Histologic grade
G1 9 2 27
G2 2 2 10
G3 1 0 0
Chemotherapy treatment (Dukes’ C stage)
Yes 0 0 0
No 0 0 0
Onda et al22: Japan
Total 14 0 31
Age, years
 50 0 0 6
50-75 9 0 23
 75 5 0 2
(continued on following page)
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Appendix: Supplementary Table. Patient and Tumor Characteristics From Individual Study Centers That Contributed Data to the
TP53-CRC Meta-Analysis (continued)
Characteristic No. Proximal Colon No. Distal Colon No. Rectum
Sex
Male 6 0 18
Female 8 0 13
Dukes’ stage
A 5 0 6
B 4 0 10
C 5 0 13
D 0 0 1
Histologic grade
G1 7 0 10
G2 7 0 18
G3 0 0 1
Chemotherapy treatment (Dukes’ C stage)
Yes 5 0 11
No 0 0 2
Kampman et al23: Netherlands
Total 77 21 74
Age, years
 50 13 1 12
50-75 59 20 58
 75 5 0 4
Sex
Male 40 14 46
Female 37 7 28
Dukes’ stage
A 4 4 17
B 41 13 28
C 21 4 22
D 10 0 7
Histologic grade
G1 14 2 11
G2 33 12 49
G3 29 5 12
Chemotherapy treatment (Dukes’ C stage)
Yes 5 1 5
No 16 3 16
Lothe et al24: Norway
Total 67 11 143
Age, years
 50 3 2 14
50-75 41 7 88
 75 23 2 41
Sex
Male 36 5 64
Female 31 6 79
Dukes’ stage
A 6 1 25
B 29 7 63
C 23 2 42
D 9 1 13
Histologic grade
G1 18 2 11
G2 45 9 122
G3 4 0 10
Chemotherapy treatment (Dukes’ C stage)
Yes 0 0 0
No 0 0 0
Guzinska et al: Poland
Total 6 1 40
Age, years
 50 1 0 6
50-75 5 1 27
 75 0 0 7
(continued on following page)
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Appendix: Supplementary Table. Patient and Tumor Characteristics From Individual Study Centers That Contributed Data to the
TP53-CRC Meta-Analysis (continued)
Characteristic No. Proximal Colon No. Distal Colon No. Rectum
Sex
Male 4 1 23
Female 2 0 17
Dukes’ stage
A 0 0 1
B 0 0 4
C 6 0 35
D 0 1 0
Histologic grade
G1 0 0 2
G2 3 0 29
G3 2 1 4
Chemotherapy treatment (Dukes’ C stage)
Yes 3 0 12
No 3 1 23
Ostrowski et al25: Poland
Total 11 2 37
Age, years
 50 1 0 9
50-75 8 1 27
 75 2 1 1
Sex
Male 4 0 23
Female 7 2 14
Dukes’ stage
A 0 0 6
B 4 2 11
C 5 0 12
D 2 0 6
Histologic grade
G1 1 0 4
G2 8 2 29
G3 2 0 1
Chemotherapy treatment (Dukes’ C stage)
Yes 4 0 9
No 1 0 3
Capellà et al26: Spain
Total 48 16 99
Age, years
 50 5 1 7
50-75 32 11 65
 75 11 4 27
Sex
Male 32 6 63
Female 16 10 36
Dukes’ stage
A 2 2 21
B 22 8 28
C 16 3 34
D 7 3 14
Histologic grade
G1 0 0 0
G2 40 14 91
G3 8 1 7
Chemotherapy treatment (Dukes’ C stage)
Yes 9 2 17
No 7 1 17
Lonnroth et al27: Sweden
Total 41 1 52
(continued on following page)
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Appendix: Supplementary Table. Patient and Tumor Characteristics From Individual Study Centers That Contributed Data to the
TP53-CRC Meta-Analysis (continued)
Characteristic No. Proximal Colon No. Distal Colon No. Rectum
Age, years
 50 1 0 8
50-75 28 1 42
 75 12 0 2
Sex
Male 15 0 36
Female 26 1 16
Dukes’ stage
A 3 0 1
B 16 1 22
C 21 0 25
D 1 0 4
Histologic grade
G1 1 1 2
G2 21 0 45
G3 18 0 4
Chemotherapy treatment (Dukes’ C stage)
Yes 0 0 0
No 21 0 25
Sun et al28: Sweden
Total 25 1 47
Age, years
 50 0 0 1
50-75 15 1 27
 75 10 0 19
Sex
Male 9 0 25
Female 16 1 22
Dukes’ stage
A 2 0 11
B 7 0 9
C 9 1 15
D 7 0 12
Histologic grade
G1 1 0 4
G2 16 1 31
G3 2 0 5
Chemotherapy treatment (Dukes’ C stage)
Yes 0 0 0
No 9 1 15
Bouzourene et al29: Switzerland
Total 61 27 35
Age, years
 50 2 0 4
50-75 35 15 26
 75 24 12 5
Sex
Male 33 13 21
Female 28 14 14
Dukes’ stage
A 0 0 0
B 61 27 35
C 0 0 0
D 0 0 0
Histologic grade
G1 13 2 3
G2 36 23 29
G3 12 1 3
Chemotherapy treatment (Dukes’ C stage)
Yes 0 0 0
No 0 0 0
(continued on following page)
Russo et al
18 JOURNAL OF CLINICAL ONCOLOGY
Copyright © 2005 by the American Society of Clinical Oncology. All rights reserved. 
Downloaded from www.jco.org by FABIO FULFARO on September 20, 2005 . 
Appendix: Supplementary Table. Patient and Tumor Characteristics From Individual Study Centers That Contributed Data to the
TP53-CRC Meta-Analysis (continued)
Characteristic No. Proximal Colon No. Distal Colon No. Rectum
Hsieh et al30: Taiwan
Total 35 18 129
Age, years
 50 5 5 30
50-75 27 11 87
 75 3 2 12
Sex
Male 19 7 79
Female 16 11 50
Dukes’ stage
A 1 1 15
B 14 9 50
C 19 8 60
D 0 0 4
Histologic grade
G1 8 3 27
G2 21 11 94
G3 6 4 7
Chemotherapy treatment (Dukes’ C stage)
Yes 13 4 44
No 6 4 16
Allan-Mersh et al31: United Kingdom
Total 2 2 7
Age, years
 50 1 0 1
50-75 1 2 6
 75 0 0 0
Sex
Male 2 0 5
Female 0 2 2
Dukes’ stage
A 0 0 0
B 0 0 0
C 2 2 5
D 0 0 2
Histologic grade
G1 0 0 0
G2 0 0 0
G3 0 0 0
Chemotherapy treatment (Dukes’ C stage)
Yes 2 2 5
No 0 0 0
Royds et al32: United Kingdom
Total 4 0 15
Age, years
 50 0 0 0
50-75 2 0 12
 75 2 0 3
Sex
Male 3 0 8
Female 1 0 7
Dukes’ stage
A 0 0 2
B 1 0 7
C 1 0 1
D 2 0 5
Histologic grade
G1 0 0 1
G2 1 0 10
G3 3 0 4
(continued on following page)
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